Company Filing History:
Years Active: 2022-2025
Title: Anzhi Yao: Innovator in Antibody and Immune Cell Technologies
Introduction
Anzhi Yao is a prominent inventor based in San Francisco, CA, known for his significant contributions to the fields of antibody and immune cell technologies. With a total of 4 patents, Yao has made remarkable strides in developing systems that enhance the efficacy of immune responses against specific cancer markers.
Latest Patents
Yao's latest patents include innovative systems targeting PSMA and CA9. These patents provide antibodies and chimeric priming receptors that bind to PSMA, as well as antibodies and chimeric antigen receptors that bind to CA9. Additionally, the patents describe systems of chimeric priming receptors that bind PSMA and chimeric antigen receptors that bind CA9, along with cells expressing such systems and methods of use thereof. Another notable patent involves immune cells that have co-expressed shRNAs and logic gate systems. This invention includes recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA targeting FAS, PTPN2, and/or TOX. The patent also outlines systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA targeting FAS, PTPN2, and/or TOX, along with cells expressing these proteins and shRNA, and methods of use thereof.
Career Highlights
Anzhi Yao is currently associated with Arsenal Biosciences, Inc., where he continues to push the boundaries of research in immunotherapy. His work focuses on creating advanced therapeutic solutions that can significantly improve patient outcomes in cancer treatment.
Collaborations
Yao collaborates with talented individuals such as Aaron Cooper and Michelle Nguyen, who contribute to the innovative environment at Arsenal Biosciences, Inc. Their combined expertise fosters a dynamic approach to tackling complex challenges in the field of biotechnology.
Conclusion
Anzhi Yao's contributions to antibody and immune cell technologies exemplify the innovative spirit of modern science. His patents and ongoing research hold promise for advancing cancer therapies and improving patient care.